DV
Dividend Vision

ALLO — Allogene Therapeutics, Inc.

Allogene Therapeutics, Inc. (ALLO)

Total return is -91.8% over the past 7.8 years, 312.5 points behind SPY at 220.7%. Its deepest 1-year drawdown was 45.8%.

ALLO is an equity stock that focuses on the therapeutic development sector. The fund does not currently distribute dividends to shareholders and therefore carries no yield profile or stated distribution frequency. This asset appeals primarily to growth-oriented investors seeking exposure to the cell and gene therapy space rather than to income-focused investors.

ALLO key facts

Asset type
Stock
Asset class
Equity
Inception date
10/11/2018
Distribution frequency
None
Last close
$2.05
Market cap
$707,566,848
Average volume
4605146.0
Beta
0.466
Payout ratio
0.0
Forward P/E
0.0
EPS
$-0.66